Definium Therapeutics
DFTX
195 hedge funds and large institutions have $469M invested in Definium Therapeutics in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 23 closing their positions.
96% more call options, than puts
Call options by funds: $21.3M | Put options by funds: $10.9M
73% more capital invested
Capital invested by funds: $271M → $469M (+$198M)
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
17% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 48
8% more funds holding
Funds holding: 181 → 195 (+14)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.09% less ownership
Funds ownership: 55.32% → 52.23% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.18M |
| 2 |
O
OrbiMed
New York
|
+$3.43M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$3.08M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.8M |
| 5 |
Two Sigma Investments
New York
|
+$2.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$16.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$9.69M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.33M |
| 4 |
Blackstone Inc
New York
|
-$7.56M |
| 5 |
ABG
Ally Bridge Group
New York
|
-$3.4M |
DFTX Hedge Fund Activity: Q3 2025 in Review
195 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2025, worth a combined $469M — up 73% from $271M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new DFTX positions and 23 closed out — a net gain of 16 holders — while 56 added to existing stakes and 48 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $4.18M. The largest seller was Commodore Capital, cutting an estimated $16.6M.
- 195 institutional investors held Definium Therapeutics (DFTX) as of Q3 2025, up from 181 in Q2 2025.
- Funds reported $469M of Definium Therapeutics stock for Q3 2025, up 73% quarter-over-quarter.
- 39 funds opened new Definium Therapeutics positions in Q3 2025 and 23 closed out, a net change of +16 holders.
- The largest Definium Therapeutics buyer in Q3 2025 was Goldman Sachs, an estimated $4.18M added.
- The largest Definium Therapeutics seller in Q3 2025 was Commodore Capital, an estimated $16.6M sold.
Based on aggregated 13F filings for Q3 2025.